← Back
NeuroTrials.ai
Neurology Clinical Trial Database

RESCUE-ALS

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension

Year of Publication: 2023

Authors: Steve Vucic, Parvathi Menon, William Huynh, ..., Matthew C Kiernan

Journal: eClinicalMedicine (The Lancet)

Citation: eClinicalMedicine 2023; 60: 102036

Link: https://doi.org/10.1016/j.eclinm.2023.102036


Clinical Question

Does CNM-Au8, a catalytically-active gold nanocrystal neuroprotective agent that enhances intracellular energy metabolism, slow ALS disease progression as measured by motor unit number index (MUNIX) and clinical outcomes?

Bottom Line

CNM-Au8 did not meet the primary MUNIX endpoint but showed clinically meaningful exploratory benefits including reduced disease progression events (55% absolute risk reduction) and significantly improved long-term survival (60% mortality reduction at 12-month follow-up). The novel use of neurophysiology as primary outcome advances clinical framework for ALS trials.

Major Points

  • Primary endpoint not met: summated MUNIX percent change -31.8% vs -39.6% (LS mean difference 7.7%, p=0.43)
  • Limb-onset subgroup showed trend favoring CNM-Au8 (LS mean difference 20.9%, p=0.074)
  • Bulbar-onset patients showed minimal MUNIX decline regardless of treatment, confounding results
  • ALS disease progression events (death, tracheostomy, NIV, gastrostomy) significantly reduced: 78% vs 23% event-free at week 36 (p=0.0125)
  • Significant 60% reduction in all-cause mortality at 12-month follow-up (HR 0.408, p=0.0429)
  • Quality of life (ALSSQOL-SF) decline significantly slowed (LS mean difference 0.9, p=0.018)
  • Proportion free from >=6-point ALSFRS-R decline: 48% vs 18% (30% absolute risk reduction)
  • CNM-Au8 well tolerated with no safety signals; TEAEs balanced between groups
  • First ALS clinical trial to utilize neurophysiological biomarker as primary outcome

Design

Study Type: Phase 2, randomized, double-blind, placebo-controlled trial with open-label extension

Randomization: 1

Blinding: Double-blind: computerized block randomization in blocks of four by independent statistician. Unblinded pharmacist at each site dispensed medication. All other personnel blinded. OLE participants and clinicians remained blinded to original randomization.

Enrollment Period: December 19, 2019 to November 2, 2020 (screening); January 16, 2020 (FPFV) to July 13, 2021 (double-blind LPLV)

Follow-up Duration: 36 weeks double-blind + open-label extension (ongoing) + survival follow-up through at least 12 months post-LPLV

Centers: 2

Countries: Australia

Sample Size: 45

Analysis: Intention-to-treat. Primary endpoint by MMRM with treatment, visit, treatment-by-visit interaction as fixed effects, ENCALS risk score as covariate. Exploratory endpoints by chi-square or MMRM. Survival by Kaplan-Meier and log-rank test. SAS 9.4.


Inclusion Criteria

  • Diagnosis of possible, probable, or definite ALS per Awaji-Shima criteria
  • Newly symptomatic within 24 months of screening or within 12 months of diagnosis
  • Age 30-80 years at diagnosis
  • FVC >=60% of predicted
  • If on riluzole, stable dose for >=30 days prior to screening

Exclusion Criteria

  • History of >=2 relatives with ALS or motor neuron disease (familial ALS)
  • Carpal tunnel syndrome
  • Other compressive neuropathies
  • Polyneuropathy

Arms

FieldControlCNM-Au8 30 mg
InterventionBuffered USP-grade water, color-matched with food-grade colorants, 60 mL oral daily at least 30 minutes prior to food intake for 36 weeksCNM-Au8 (catalytically-active gold nanocrystal suspension 500 ug/mL in USP-grade deionized water buffered with sodium bicarbonate), 60 mL (30 mg) oral daily at least 30 minutes prior to food intake for 36 weeks
Duration36 weeks double-blind36 weeks double-blind + open-label extension

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Mean percent change from baseline to week 36 of summated MUNIX score (ADM, APB, BB, TA), indexed to baseline as 100%Primary-39.6% (SE 7.1)-31.8% (SE 6.6)7.80%0.43
Mean total MUNIX score change at week 36Secondary-141 (SE 27)-123 (SE 25)
FVC (% predicted) change at week 36Secondary-20.3 (SE 5.8)-16.7 (SE 5.4)
Limb-onset subgroup: summated MUNIX % changeSecondary-46.7%-25.8%0.074
ALS disease progression events (death/tracheostomy/NIV/gastrostomy) - % event-free at week 36Secondary23% (95% CI 0-55%)78% (95% CI 61-95%)0.0125
Proportion free from >=6-point ALSFRS-R declineSecondary18%48%0.035
ALSSQOL-SF changeSecondary-1.2 (SE 0.3)-0.3 (SE 0.2)0.018
ALSFRS-R total score change at week 36Secondary-5.8 (SE 0.9)-4.8 (SE 0.8)
Mortality at 12-month follow-up post-LPLVSecondary15/22 deaths (68%)7/23 deaths (30%)HR 0.408 (95% Wald CI 0.166-1.001)0.0429
Participants with >=1 TEAEAdverse17 (77.3%)17 (73.9%)
FallAdverse3 (13.6%)2 (8.7%)
Aspiration pneumoniaAdverse03 (13.0%)
LacerationAdverse3 (13.6%)0
ContusionAdverse02 (8.7%)
NauseaAdverse02 (8.7%)
TEAE Severity - MildAdverse13 (59.1%)14 (60.9%)
TEAE Severity - ModerateAdverse5 (22.7%)7 (30.4%)
TEAE Severity - SevereAdverse6 (27.3%)3 (13.0%)
Related TEAEsAdverse2 (9%)3 (13%)
Serious adverse eventsAdverse5 (22.7%)5 (21.7%)
Deaths during double-blind periodAdverse21

Subgroup Analysis

Limb-onset patients (n=33, 73%) showed greater MUNIX decline in placebo group (-46.7%) approaching a priori assumptions, with trend favoring CNM-Au8 (LS mean difference 20.9%, p=0.074). Bulbar-onset patients (n=12) showed minimal MUNIX decline in placebo group (-7.9%) despite spinal cord-innervated muscles being measured. Post hoc interaction test (onset site x treatment) p=0.0783 - insufficient evidence for differential treatment response. OLE random slopes analysis showed continued benefit for originally CNM-Au8 randomized patients through week 120.


Criticisms

  • Small sample size (n=45) vulnerable to baseline imbalances
  • Primary endpoint not met - exploratory outcomes require cautious interpretation
  • Bulbar-onset patients did not show expected MUNIX decline, confounding results
  • Selection of MUNIX as primary endpoint limited by disease heterogeneity
  • Selection of 4 spinal cord-innervated muscles may not capture bulbar phenotype decline
  • Placebo group had some baseline disadvantages (older, lower FVC, higher delta-FS, less riluzole use)
  • Two-site study limits generalizability and may have contributed to underpowering
  • No site-level stratification in statistical analysis
  • Slow CNM-Au8 absorption (3-4 weeks for detectable blood levels, >6 months for tissue equilibrium) may explain lack of 24-week efficacy
  • OLE participation was optional, introducing selection bias
  • Survival benefit sensitivity analysis with lost-to-follow-up imputed as deaths was not significant (p=0.126)

Funding

FightMND (Australia) with additional funding from Clene Australia Pty Ltd (subsidiary of Clene Nanomedicine, Inc.)

Based on: RESCUE-ALS (eClinicalMedicine (The Lancet), 2023)

Authors: Steve Vucic, Parvathi Menon, William Huynh, ..., Matthew C Kiernan

Citation: eClinicalMedicine 2023; 60: 102036

Content summarized and formatted by NeuroTrials.ai.